PubMed

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.PMID: 8866556 [PubMed - indexed for MEDLINE]Related articles

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

Greenbaum CJ, Prigeon RL, D'Alessio DA.

Diabetes. 2002 Apr;51(4):951-7.PMID: 11916912 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.

Diabetes Care. 1996 Aug;19(8):857-63.PMID: 8842604 [PubMed - indexed for MEDLINE]Related articles

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Kjems LL, Holst JJ, Vølund A, Madsbad S.

Diabetes. 2003 Feb;52(2):380-6.PMID: 12540611 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.

Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.

Diabetes. 1998 Aug;47(8):1259-65.PMID: 9703326 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.

Diabetes. 1998 Jan;47(1):45-9.PMID: 9421373 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.

Diabetes. 2001 Apr;50(4):776-84.PMID: 11289042 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.

Ahrén B, Holst JJ, Mari A.

Diabetes Care. 2003 Oct;26(10):2860-4.PMID: 14514592 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

Rachman J, Barrow BA, Levy JC, Turner RC.

Diabetologia. 1997 Feb;40(2):205-11.PMID: 9049482 [PubMed - indexed for MEDLINE]Related articles

Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.

Juhl CB, Schmitz O, Pincus S, Holst JJ, Veldhuis J, Pørksen N.

Diabetologia. 2000 May;43(5):583-8.PMID: 10855533 [PubMed - indexed for MEDLINE]Related articles

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.

Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M.

Diabetologia. 2000 Jul;43(7):852-8.PMID: 10952457 [PubMed - indexed for MEDLINE]Related articles

Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia.

Ryan AS, Egan JM, Habener JF, Elahi D.

J Clin Endocrinol Metab. 1998 Jul;83(7):2399-404.PMID: 9661618 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

Diabetes Care. 1997 Dec;20(12):1874-9.PMID: 9405910 [PubMed - indexed for MEDLINE]Related articles